Bharat Biotech on Thursday announced that it has ramped up additional manufacturing capacities for its COVID-19 vaccine Covaxin at the Chiron Behring facility in Gujarat's Ankleshwar.
Chiron Behring is a subsidiary of Bharat Biotech. The company said it plans to produce 200 million additional Covaxin doses annually at these facilities.
“The company plans to produce 200 million doses of COVAXIN per annum in the GMP facilities that are already operational for the production of vaccines based on Inactivated Vero Cell Platform Technology, under stringent levels of GMP and biosafety,” Bharat Biotech said in a statement
It said that the addition in manufacturing capabilities would take the vaccine production volume up to 1 billion per annum.
“This effectively takes the volumes upto around 1 Billion doses per annum, with its own established campuses specialised for manufacturing inactivated viral vaccines under the highest levels of biosafety,” added the statement.
The Ankleshwar-based plant would start rolling out the much in demand vaccine from the fourth quarter of the year, it added. The company said it has already deployed multiple production lines at its Hyderabad and Bengaluru campuses.
(Edited by : Aditi Gautam)
First Published: May 20, 2021 9:09 PM IST
Check out our in-depth Market Coverage, Business News & get real-time Stock Market Updates on CNBC-TV18. Also, Watch our channels CNBC-TV18, CNBC Awaaz and CNBC Bajar Live on-the-go!
Supreme Court says it may consider interim bail for Arvind Kejriwal due to ongoing Lok Sabha polls
May 3, 2024 4:57 PM
10% discount on fare on Mumbai Metro lines 2 and 7A on May 20
May 3, 2024 2:40 PM